Rockefeller Capital Management
TVTX icon

Rockefeller Capital Management’s Travere Therapeutics TVTX Stock Holding History

Rockefeller Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$450K Sell
7,927
-182
-2% -$8.07K ﹤0.01% 2138
2026
Q1 		$241K Buy
8,109
+5,467
+207% +$163K ﹤0.01% 2386
2025
Q4 		$101K Buy
2,642
+2,487
+1,605% +$80.9K ﹤0.01% 2725
2025
Q3 		$3.71K Buy
+155
New +$2.91K ﹤0.01% 3964
2022
Q3 		– Sell
-94
Closed -$2K – 4380
2022
Q2 		$2K Sell
94
-62
-40% -$1.56K ﹤0.01% 3841
2022
Q1 		$4K Sell
156
-487
-76% -$12.9K ﹤0.01% 3450
2021
Q4 		$19K Buy
+643
New +$18.1K ﹤0.01% 2675

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rockefeller Capital Management's TVTX Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Travere Therapeutics (TVTX) stake by 2.2% in Q2 2026, selling an estimated $8.07K and leaving 7,927 shares worth $450K. The position accounts for ﹤0.01% of the portfolio, ranked #2138.

Rockefeller Capital Management first reported a position in TVTX in Q4 2021 and has held it in 7 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Rockefeller Capital Management held 7,927 shares of Travere Therapeutics worth $450K as of Q2 2026.
  • Rockefeller Capital Management sold 182 Travere Therapeutics shares in Q2 2026, an estimated $8.07K.
  • Travere Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #2138 holding.
  • Rockefeller Capital Management first reported a position in Travere Therapeutics in Q4 2021 and has held it in 7 quarters since.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.